Search Within

Population Sciences Research Program

Refine Results
  1. "Matthew Matasar"
  2. "Survivorship Research"
  3. "Carol Portlock"
  4. "Adult Bone Marrow Transplant (BMT) Service"
  5. "Alison Moskowitz"
Formats
  1. Journal Article (3)
  2. Meeting Abstract (3)
Groups
  1. Adult Bone Marrow Transplant (BMT) Service (6)
  2. Bone Marrow Transplant (6)
  3. Center for Hematologic Malignancies (6)
  4. Hematologic Oncology, Division of (6)
  5. Lymphoma (6)
  6. Survivorship Research (6)

More Groups

People
  1. Alison Moskowitz (6)
  2. Andrew Zelenetz (6)
  3. Ariela Noy (6)
  4. Carol Portlock (6)
  5. Craig Moskowitz (6)
  6. David Straus (6)

More People

Years
  1. 2017 (3)
  2. 2016 (1)
  3. 2015 (1)
  4. 2013 (1)
Publications
  1. Hematological Oncology (2)
  2. Blood (1)
  3. Haematologica (1)
  4. Journal of Clinical Oncology (1)
  5. Lancet Oncology (1)
Publishers
  1. Wiley Blackwell (2)
  2. American Society of Clinical Oncology (1)
  3. American Society of Hematology (1)
  4. Elsevier Science, Inc. (1)
  5. Ferrata Storti Foundation (1)

Results (6)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Cadzin, B. R.; Fox, S. Y.; Gerecitano, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Defining progression free survival after multiple lines of therapy and impact of dynamic changes in FLIPI for multiply relapsed follicular lymphoma in the rituximab era
    Meeting Abstract

    Batlevi, C.; Alperovich, A.; Ni, A.; Soumerai, J.; Smith, K.; Ying, Z.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PET-adapted salvage therapy with brentuximab vedotin and augmented ICE
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • PET-adapted therapy with brentuximab vedotin and augmented ICE for relapsed/refractory Hodgkin lymphoma - Lack of Improvement with 3 versus 2 cycles of weekly brentuximab vedotin
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: A non-randomised, open-label, single-centre, phase 2 study
    Journal Article

    Moskowitz, A. J.; Schöder, H.; Yahalom, J.; Mccall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Lancet Oncology (2015)

    Fulltext@MSK | Save
  • Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Hamlin, P. A. Jr; Perales, M. A.; Gerecitano, J.; Horwitz, S. M.; Matasar, M. J.; Noy, A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save